PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-168.99%
Negative EBIT growth while AXSM is at 23.84%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-230.56%
Negative operating income growth while AXSM is at 35.57%. Joel Greenblatt would press for urgent turnaround measures.
-176.90%
Negative net income growth while AXSM stands at 19.26%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
89.62%
EPS growth above 1.5x AXSM's 20.49%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
89.62%
Diluted EPS growth above 1.5x AXSM's 20.49%. David Dodd would see if there's a robust moat protecting these shareholder gains.
2567.99%
Share count expansion well above AXSM's 1.17%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
2567.99%
Diluted share count expanding well above AXSM's 1.17%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-298628.16%
Negative OCF growth while AXSM is at 25.25%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-217028.56%
Negative FCF growth while AXSM is at 25.25%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-67594.88%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-60146.79%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-86002.39%
Negative 3Y OCF/share CAGR while AXSM stands at 23.58%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-51844.29%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-93706.66%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-45701.99%
Negative 3Y CAGR while AXSM is 11.48%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
3346.07%
10Y equity/share CAGR above 1.5x AXSM's 360.64%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
1899.20%
Positive 5Y equity/share CAGR while AXSM is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
720.41%
3Y equity/share CAGR above 1.5x AXSM's 280.02%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
104.51%
Asset growth above 1.5x AXSM's 7.23%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
-98.43%
We have a declining book value while AXSM shows 35.76%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
92.16%
Debt growth far above AXSM's 2.81%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-30.73%
Our R&D shrinks while AXSM invests at 10.62%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
522.30%
SG&A growth well above AXSM's 7.86%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.